|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5572 USD | -0.05% |
|
-2.93% | -3.95% |
| Dec. 18 | RTW Biotech Opportunities announces new investment in Yarrow Bioscience | RE |
| Dec. 17 | VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 20.99M | 14.76M | 477K | 424K | 501K | |||||
Total Revenues | 20.99M | 14.76M | 477K | 424K | 501K | |||||
Cost of Goods Sold, Total | 1.39M | 3.35M | - | - | - | |||||
Gross Profit | 19.6M | 11.41M | 477K | 424K | 501K | |||||
Selling General & Admin Expenses, Total | 77.14M | 54.48M | 16.39M | 13.38M | 13.19M | |||||
R&D Expenses | 39.73M | 24.96M | 18.38M | 16.31M | 30.95M | |||||
Other Operating Expenses, Total | 117M | 79.44M | 34.77M | 29.68M | 44.14M | |||||
Operating Income | -97.28M | -68.03M | -34.3M | -29.26M | -43.64M | |||||
Interest Expense, Total | -4.39M | -5.61M | - | - | - | |||||
Interest And Investment Income | - | - | - | 1.39M | 3.83M | |||||
Net Interest Expenses | -4.39M | -5.61M | - | 1.39M | 3.83M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | 968K | -135K | 363K | - | - | |||||
EBT, Excl. Unusual Items | -101M | -73.78M | -33.93M | -27.87M | -39.8M | |||||
Merger & Related Restructuring Charges | -16.2M | - | - | - | - | |||||
Impairment of Goodwill | -4.54M | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 142K | - | - | - | - | |||||
In Process R&D Expenses | -49.8M | - | - | - | - | |||||
Other Unusual Items | -84.73M | - | - | - | - | |||||
EBT, Incl. Unusual Items | -256M | -73.78M | -33.93M | -27.87M | -39.8M | |||||
Income Tax Expense | -258K | -448K | 13K | - | 4K | |||||
Earnings From Continuing Operations | -256M | -73.33M | -33.94M | -27.87M | -39.81M | |||||
Earnings Of Discontinued Operations | - | - | 10.74M | -580K | -27K | |||||
Net Income to Company | -256M | -73.33M | -23.21M | -28.45M | -39.83M | |||||
Net Income - (IS) | -256M | -73.33M | -23.21M | -28.45M | -39.83M | |||||
Preferred Dividend and Other Adjustments | - | - | - | 149K | - | |||||
Net Income to Common Incl Extra Items | -256M | -73.33M | -23.21M | -28.6M | -39.83M | |||||
Net Income to Common Excl. Extra Items | -256M | -73.33M | -33.94M | -28.02M | -39.81M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -141.9 | -25.64 | -7.28 | -2.78 | -0.94 | |||||
Basic EPS - Continuing Operations | -141.9 | -25.64 | -10.65 | -2.73 | -0.93 | |||||
Basic Weighted Average Shares Outstanding | 1.8M | 2.86M | 3.19M | 10.27M | 42.59M | |||||
Net EPS - Diluted | -141.9 | -25.64 | -7.28 | -2.78 | -0.94 | |||||
Diluted EPS - Continuing Operations | -141.9 | -25.64 | -10.65 | -2.73 | -0.93 | |||||
Diluted Weighted Average Shares Outstanding | 1.8M | 2.86M | 3.19M | 10.27M | 42.59M | |||||
Normalized Basic EPS | -34.94 | -16.13 | -6.66 | -1.7 | -0.58 | |||||
Normalized Diluted EPS | -34.94 | -16.13 | -6.66 | -1.7 | -0.58 | |||||
Supplemental Items | ||||||||||
EBITDA | -96.93M | -67.92M | -34.22M | -29.19M | -43.63M | |||||
EBITA | -97.28M | -68.03M | -34.3M | -29.26M | -43.64M | |||||
EBIT | -97.28M | -68.03M | -34.3M | -29.26M | -43.64M | |||||
EBITDAR | -95.58M | -67.13M | -33.93M | -29.08M | -43.5M | |||||
Total Revenues (As Reported) | 20.99M | 14.76M | 477K | 424K | 501K | |||||
Effective Tax Rate - (Ratio) | 0.1 | 0.61 | -0.04 | - | -0.01 | |||||
Current Domestic Taxes | -253K | -448K | 13K | -121K | 4K | |||||
Current Foreign Taxes | - | - | - | 121K | - | |||||
Total Current Taxes | -253K | -448K | 13K | 0 | 4K | |||||
Normalized Net Income | -62.94M | -46.11M | -21.21M | -17.42M | -24.88M | |||||
Interest on Long-Term Debt | 4.4M | 5.6M | - | - | - | |||||
Non-Cash Pension Expense | 8.5M | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 43.53M | 24.96M | 18.38M | 16.31M | 30.95M | |||||
Net Rental Expense, Total | 1.35M | 791K | 297K | 102K | 136K | |||||
Imputed Operating Lease Interest Expense | 1.37M | 2.02M | - | - | - | |||||
Imputed Operating Lease Depreciation | -19.23K | -1.23M | - | - | - | |||||
Stock-Based Comp., COGS (Total) | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 4.75M | 1.71M | 1.23M | 534K | 548K | |||||
Stock-Based Comp., SG&A Exp. (Total) | 13.35M | 6.37M | 3.42M | 2.77M | 2.76M | |||||
Total Stock-Based Compensation | 18.1M | 8.08M | 4.65M | 3.3M | 3.3M |
- Stock Market
- Equities
- VYNE Stock
- Financials VYNE Therapeutics Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















